oncnursingnews12h
Amezalpat Receives FDA Fast Track Designation for Hepatocellular Carcinoma
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
gastroenterologyadvisor16h
Amezalpat Gets Fast Track Status for Hepatocellular Carcinoma
The FDA has granted Fast Track designation to amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma.